469 related articles for article (PubMed ID: 24726140)
1. CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling.
Ma MZ; Zhuang C; Yang XM; Zhang ZZ; Ma H; Zhang WM; You H; Qin W; Gu J; Yang S; Cao H; Zhang ZG
Neoplasia; 2014 Mar; 16(3):265-78, 278.e1-13. PubMed ID: 24726140
[TBL] [Abstract][Full Text] [Related]
2. CTHRC1 overexpression promotes cervical carcinoma progression by activating the Wnt/PCP signaling pathway.
Zheng M; Zhou Q; Liu X; Wang C; Liu G
Oncol Rep; 2019 Mar; 41(3):1531-1538. PubMed ID: 30628714
[TBL] [Abstract][Full Text] [Related]
3. CTHRC1 promotes human colorectal cancer cell proliferation and invasiveness by activating Wnt/PCP signaling.
Yang XM; You HY; Li Q; Ma H; Wang YH; Zhang YL; Zhu L; Nie HZ; Qin WX; Zhang ZG; Li J
Int J Clin Exp Pathol; 2015; 8(10):12793-801. PubMed ID: 26722469
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal stromal tumors (GIST): a single center experience.
Kostka R; Gürlich R; Koldová L
Acta Chir Belg; 2012 Jan; 112(1):33-9. PubMed ID: 22442907
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors.
Jiang J; Jin MS; Suo J; Wang YP; He L; Cao XY
World J Gastroenterol; 2012 May; 18(20):2569-75. PubMed ID: 22654456
[TBL] [Abstract][Full Text] [Related]
7. E6/E7-P53-POU2F1-CTHRC1 axis promotes cervical cancer metastasis and activates Wnt/PCP pathway.
Zhang R; Lu H; Lyu YY; Yang XM; Zhu LY; Yang GD; Jiang PC; Re Y; Song WW; Wang JH; Zhang CC; Gu F; Luo TJ; Wu ZY; Xu CJ
Sci Rep; 2017 Mar; 7():44744. PubMed ID: 28303973
[TBL] [Abstract][Full Text] [Related]
8. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
[TBL] [Abstract][Full Text] [Related]
9. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis.
Chen YL; Wang TH; Hsu HC; Yuan RH; Jeng YM
PLoS One; 2013; 8(7):e70324. PubMed ID: 23922981
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
12. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.
Zhi X; Zhou X; Wang W; Xu Z
PLoS One; 2013; 8(11):e79275. PubMed ID: 24223922
[TBL] [Abstract][Full Text] [Related]
13. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
Zhang L; Cai M; Deng J; Wang X; Wang B; Liu N; Pan Y; Zhang R; Cui Q; Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):331-4. PubMed ID: 24760639
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit.
Pelczar P; Zibat A; van Dop WA; Heijmans J; Bleckmann A; Gruber W; Nitzki F; Uhmann A; Guijarro MV; Hernando E; Dittmann K; Wienands J; Dressel R; Wojnowski L; Binder C; Taguchi T; Beissbarth T; Hogendoorn PC; Antonescu CR; Rubin BP; Schulz-Schaeffer W; Aberger F; van den Brink GR; Hahn H
Gastroenterology; 2013 Jan; 144(1):134-144.e6. PubMed ID: 23041331
[TBL] [Abstract][Full Text] [Related]
16. CTHRC1 overexpression promotes ectopic endometrial stromal cell proliferation, migration and invasion via activation of the Wnt/β-catenin pathway.
Lv Y; Zhang L; Ma J; Fei X; Xu K; Lin J
Reprod Biomed Online; 2020 Jan; 40(1):26-32. PubMed ID: 31787549
[TBL] [Abstract][Full Text] [Related]
17. N-glycosylation induces the CTHRC1 protein and drives oral cancer cell migration.
Liu G; Sengupta PK; Jamal B; Yang HY; Bouchie MP; Lindner V; Varelas X; Kukuruzinska MA
J Biol Chem; 2013 Jul; 288(28):20217-27. PubMed ID: 23703614
[TBL] [Abstract][Full Text] [Related]
18. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal stromal tumours (GISTs): case report and review of the literature.
Al-Amri AM; Shawarbi MA; El-Hassan AY; Al-Johi KS
Gulf J Oncolog; 2011 Jan; (9):57-60. PubMed ID: 21177210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
